Introduction: Niaspan, an extended-release formulation of Niacin (vitamin B3), has been widely used to increase high density lipoprotein (HDL) cholesterol and to prevent cardiovascular diseases and stroke. In this study, we tested whether Niaspan administered acutely after stroke is neuroprotective. Methods: Adult male rats (n = 8/group) were subjected to 2 h of middle cerebral artery occlusion (MCAo) and treated with or without different doses of Niaspan (20, 40 or 80 mg/kg) at 2 and 24 h after MCAo. A battery of functional outcome tests was performed, and serum HDL and triglycerides were measured. Rats were sacrificed at 7 days after MCAo and lesion volumes were measured. The optimal dose of Niaspan treatment of stroke was chosen for immunostaining: deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), cleaved caspase-3, tumor necrosis factor alpha (TNF-alpha), vascular endothelial growth factor (VEGF) and phosphorylated phosphatidylinositol 3-kinase (p-PI3K). Another set of rats (n = 4/group) were killed at 7 days after MCAo for Western blot assay. Results: Niaspan dose-dependently reduced infarct volume and improved functional outcome after stroke. No significant difference in HDL and triglyceride levels was detected between Niaspan treatments and MCAo control groups. Niaspan treatment significantly decreased the number of TUNEL-positive cells (105 ± 17) and cleaved caspase-3 expression (381 ± 33) in the ischemic brain compared to MCAo control (165 ± 18; 650 ± 61, respectively; p ≤ 0.05). Niaspan treatment significantly reduced the expression of TNF-alpha (9.7 ± 1.1% vs. 16 ± 2.2%; p ≤ 0.05) and negative correlations were observed between the functional tests and the expression of TNF-alpha (r = −0.71, p ≤ 0.05). Niaspan treatment also significantly increased the expression of VEGF (5.2 ± 0.9%) and PI3K/Akt (0.381 ± 0.04%) in the ischemic brain compared with non-treated MCAo control (2.6 ± 0.4%; 0.24 ± 0.03, respectively; p ≤ 0.05). The functional outcome was positively correlated with p-PI3K (r = 0.7, p ≤ 0.05). Conclusions: Treatment of stroke with Niaspan at 2 h after MCAo reduces infarct volume and improves neurological outcome and provides neuroprotection. The neuroprotective effects of Niaspan were associated with reduction of apoptosis and attenuation of TNF-alpha expression. VEGF and the PI3K/Akt pathway may contribute to the Niaspan-induced neuroprotection after stroke.
Introduction
Niacin is a lipid altering agent and has been widely used to prevent cardiovascular diseases, stroke and atherosclerosis (Meyers et al., 2004) . Niacin is the most effective medication in current clinical use for increasing high density lipoprotein (HDL) cholesterol (Elam et al., 2000) . Niaspan, an extended-release formulation of Niacin (vitamin B3), reduces the Niacin-induced major side effects of flush and hepatotoxicity (Carlson, 2004) . We have previously demonstrated that Niaspan treatment of experimental stroke in rats starting 24 h after stroke, significantly increases HDL cholesterol, enhances local cerebral blood flow, promotes angiogenesis and arteriogenesis and improves functional outcome without affecting infarct volume (Chen et al., 2009; Chen et al., 2007) . Extended-release Niacin decreases the level of C-reactive protein in patients with stable coronary artery disease (Kuvin et al., 2006) and inhibits vascular inflammation (Ganji et al., 2009; Wu et al., 2010) . The inflammatory response is characterized by the local expression of various inflammatory cytokines in the brain (DeGraba, 1998) . Tumor necrosis factor alpha (TNF-alpha), which is detected as early as 1 h after the onset of ischemia, contributes to the progression of neuronal injury after stroke (Morales et al., 2008; Sehara et al., 2007; Suzuki et al., 2009) . Several different strategies to inhibit TNF-alpha effects in acute stroke have been reported to reduce the degree of ischemic injury in animal models (Shohami et al., 1999) . Niacin is metabolized in the liver to nicotinamide. Administration of Neurobiology of Disease 40 (2010) 277-283 
